HIGHLIGHTS
- who: Mathieu Larroquette and colleagues from the Department of Medical Oncology, University Hospital of Bordeaux, Bordeaux, France have published the research work: Therapeutic Management of Metastatic Clear Cell Renal Cell Carcinoma: A Revolution in Every Decade, in the Journal: Cancers 2022, 14, 6230. of /2022/
- what: The phase III CONTACT-03 study (NCT04338269), which is aimed at comparing the efficacy of cabozantinib alone vs. cabozantinib plus atezolizumab in patients who experienced disease progression under ICB therapy, is closed for randomisations .
- how: The results showed that 12% of patients (10/83) had a confirmed . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.